# Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)

> **NCT02580591** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 977 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02580591
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-22
- **Primary completion:** 2017-09-12
- **Final completion:** 2017-09-20
- **Target enrollment:** 977 (ACTUAL)
- **Last updated:** 2018-11-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02580591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02580591, "Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02580591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*